Kimberly J. Popovits - 01 Apr 2026 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Reporting relationship: Director
Issuer ticker: RYTM
Reported as of: 01 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Apr 2026, 17:35:38 UTC
Prior SEC filing: 23 Mar 2026
Next SEC filing: 02 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen Vander Stoep, attorney-in-fact for Kimberly J. Popovits

Key filing fact

Kimberly J. Popovits filed Form 4 for RHYTHM PHARMACEUTICALS, INC. (RYTM) on 03 Apr 2026.

Key facts

This page summarizes Kimberly J. Popovits's Form 4 filing for RHYTHM PHARMACEUTICALS, INC. (RYTM).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Apr 2026, 17:35.

Change

Previous filing in this sequence was filed on 23 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001333482 Primary reporting owner

Popovits Kimberly J

Relationship: Director
Address: 222 BERKELEY STREET, 12TH FLOOR, BOSTON
Signature: /s/ Stephen Vander Stoep, attorney-in-fact for Kimberly J. Popovits
Signature date: 03 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RYTM transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +6,808
Change %
Price: $0.000000^*
Shares after: 6,808
Date: 01 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,808
Exercise price
Footnotes: F1, F2

RYTM transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
Shares: +10,257
Change %
Price: $0.000000^*
Shares after: 10,257
Date: 01 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,257
Exercise price: $88.12
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Footnote F2

The restricted stock units will vest as to 33% of the total shares on each of April 1, 2027, April 1, 2028, April 1, 2029. The restricted stock units have no expiration date.

Footnote F3

The stock options were granted on April 1, 2026. The options vest and become exercisable in three substantially equal annual installments subject to the Reporting Person continuing in service through each such vesting date.